Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Semler Scientific Inc (SMLR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: SMLR (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit 18.74% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 505.93M USD | Price to earnings Ratio - | 1Y Target Price 71 |
Price to earnings Ratio - | 1Y Target Price 71 | ||
Volume (30-day avg) - | Beta 1.43 | 52 Weeks Range 21.77 - 81.56 | Updated Date 06/29/2025 |
52 Weeks Range 21.77 - 81.56 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.39 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -60.69% | Operating Margin (TTM) -15.29% |
Management Effectiveness
Return on Assets (TTM) 4.18% | Return on Equity (TTM) -24.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 592336349 | Price to Sales(TTM) 10.28 |
Enterprise Value 592336349 | Price to Sales(TTM) 10.28 | ||
Enterprise Value to Revenue 12.03 | Enterprise Value to EBITDA 7 | Shares Outstanding 13141100 | Shares Floating 10076783 |
Shares Outstanding 13141100 | Shares Floating 10076783 | ||
Percent Insiders 12.03 | Percent Institutions 50.34 |
Upturn AI SWOT
Semler Scientific Inc
Company Overview
History and Background
Semler Scientific, Inc. was founded in 2007. It focuses on developing, manufacturing, and marketing products and services that help healthcare providers manage and treat chronic diseases. The company has evolved from initial diagnostic tools to focusing on vascular assessment.
Core Business Areas
- Vascular Assessment: Semler Scientific develops and markets products for the early detection and management of peripheral arterial disease (PAD). Their main product, QuantaFlo, is a non-invasive, in-office blood flow test.
Leadership and Structure
Wayne T. Pan is the Chairman and CEO. The company has a typical organizational structure with departments for sales, marketing, research and development, and operations.
Top Products and Market Share
Key Offerings
- QuantaFlo: QuantaFlo is Semler Scientific's primary product. It is a non-invasive arterial blood flow test used to assess peripheral arterial disease (PAD). Limited precise market share data available, but QuantaFlo has a growing presence in the vascular assessment market. Competitors include companies offering Ankle-Brachial Index (ABI) testing, Pulse Volume Recording (PVR), and other vascular diagnostic solutions from companies such as Arteriotech and Medtronic
Market Dynamics
Industry Overview
The market for vascular disease diagnostics is growing due to the aging population, increasing prevalence of diabetes and obesity, and growing awareness of PAD. The industry is competitive, with established players and emerging technologies.
Positioning
Semler Scientific is positioned as a provider of cost-effective and easy-to-use vascular assessment tools, specifically targeting physicians' offices for in-office testing. Its competitive advantage lies in QuantaFlo's ease of use and integration into existing practice workflows.
Total Addressable Market (TAM)
The TAM for PAD diagnostics is estimated to be in the billions of dollars, encompassing the costs associated with diagnosis, treatment, and management of PAD. Semler Scientific is positioned to capture a portion of this market through wider adoption of its QuantaFlo technology.
Upturn SWOT Analysis
Strengths
- Proprietary technology (QuantaFlo)
- Relatively low cost compared to alternatives
- Strong focus on physician office testing
- High gross profit margins
- Strong balance sheet with no debt
Weaknesses
- Single product dependency (QuantaFlo)
- Limited brand awareness compared to larger competitors
- Reliance on reimbursement rates for PAD testing
- Smaller sales and marketing team compared to competitors
Opportunities
- Expanding into new markets and geographies
- Developing new products and services for vascular assessment
- Partnerships with healthcare providers and insurers
- Increasing awareness of PAD and the benefits of early detection
Threats
- Changes in reimbursement rates for PAD testing
- Competition from established players with more resources
- Technological advancements that could render QuantaFlo obsolete
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- MDTC
- BSX
- ABT
- GEHC
Competitive Landscape
Semler Scientific offers a focused solution for PAD assessment, which can be advantageous. Competitors have a wider range of products, providing economies of scale and broader market coverage. Semler differentiates through ease of use and specific targeting of physician offices.
Growth Trajectory and Initiatives
Historical Growth: Discuss Semler Scientific Inc's growth trends over the past years.
Future Projections: Provide projections for Semler Scientific Inc's future growth based on analyst estimates.
Recent Initiatives: Highlight recent strategic initiatives undertaken by Semler Scientific Inc.
Summary
Semler Scientific is a niche player in the vascular assessment market, focused on its QuantaFlo technology. It benefits from high gross margins and a strong balance sheet. However, it faces risks due to single-product dependency and competition from larger, more diversified companies. The company needs to strategically expand its product offerings and market presence to sustain growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Market research reports
- Analyst estimates
- Company website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Semler Scientific Inc
Exchange NASDAQ | Headquaters Santa Clara, CA, United States | ||
IPO Launch date 2014-02-21 | CEO, President & Director Dr. Douglas Murphy-Chutorian M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 79 | Website https://www.semlerscientific.com |
Full time employees 79 | Website https://www.semlerscientific.com | ||
Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.